Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Clinical Analysis of 18 Malignant Hematological Patients with Fungemia

Clinical analysis of 14 cases of candidemia

Fungemia: A Retrospective Clinical Analysis of 17 Patients

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Nosocomial Fungus Infection:A Clinical Analysis

[Pulmonary Fungal Infection in Malignant Hematological Diseases: an Analysis of 14 Cases].

Clinical and Microbiological Investigation of Fungemia from Four Hospitals in China

21-plex PCR and Antifungal Susceptibility Aspects of Fungemia Agents in Pediatric Patients with Hematological Malignancies: A Single-Center Experience

Clinical analysis of metagenome next-generation sequencing for diagnosing invasive fungal disease in patients with early stage of hematopoietic stem cell transplantation

Etiological analysis of nosocomial infections in patients with acute leukemia and clinical treatment

The Epidemiology and Clinical Characteristics of Fungemia in a Tertiary Hospital in Southern China: A 6-Year Retrospective Study

Clinical study of invasive fungal infections in hematological malignancies

Fungal infections in tumor patients and analysis of drug resistance

Clinical Features and Prognostic Risk Factors of Candidemia in Non-Intensive Care Unit Wards

Retrospective analysis of 57 patients with fungal bloodstream infection

The clinical analysis of 721 case pathogen infection in 1741 patients with hematologic diseases

[A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in patients with hematological malignancies]

Analysis of the distribution and drug resistance of pathogenic bacteria in patients with malignant hematologic disease

Clinical analysis of nosocomial fungal infections in 192 tumor patients

Clinical features and pathogens of bloodstream infections in patients with hematologic malignancy